Market Overview

UPDATE: Morgan Stanley Initiates Neurocrine Biosciences at Overweight on Asset Quality

Share:
Related NBIX
Neurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children with Tourette Syndrome
Icahn School Of Medicine At Mount Sanai Files Complaint Against Neurocrine Sciences For Breach Of Contract - 8-K Filings

Morgan Stanley initiated its coverage on Neurocrine Biosciences (NASDAQ: NBIX) with an Overweight rating and a $12 price target.

Morgan Stanley said, "Neurocrine has a differentiated lead asset, elagolix, targeting large markets with segments of unmet need. We believe the Street undervalues this asset. We expect elagolix success in endometriosis and uterine fibroids (UF) and model combined WW sales of ~$720mn in 2020."

Neurocrine Biosciences closed at $8.30 on Wednesday.

Latest Ratings for NBIX

DateFirmActionFromTo
Feb 2016JP MorganMaintainsOverweight
Jul 2015Leerink SwannAssumesOutperform
Jun 2015Piper JaffrayMaintainsOverweight

View More Analyst Ratings for NBIX
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (NBIX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters